Neuraminidase in Virus-like Particles Contributes to the Protection Against High Dose of Avian Influenza Virus Challenge Infection

Overview

Journal Pathogens

Date 2021 Oct 23

PMID 34684240

Citations 6

Authors

Hae-Ji Kang

Ki-Back Chu

Keon-Woong Yoon

Gi-Deok Eom

Jie Mao

Min-Ju Kim

Su-Hwa Lee

Eun-Kyung Moon

Fu-Shi Quan

Affiliations

Soon will be listed here.

Abstract

Neuraminidase is an important target for influenza vaccination. In this study, we generated avian influenza VLPs, expressing hemagglutinin (HA), neuraminidase (NA), HA and NA co-expressed (HANA), to evaluate the protective role of NA against a high (10LD) and low (2LD) dose of avian influenza virus challenge infections. A single immunization with HANA VLPs elicited the highest level of virus-specific IgG, IgG1, and IgG2a responses from the sera post-vaccination and the lungs post-challenge-infection. Potent antibody-secreting cell responses were observed from the spleens and lungs of HANA-VLP-immunized mice post-challenge-infection. HANA VLPs induced the highest CD4 T cell, CD8 T cell, and germinal center B cells, while strongly limiting inflammatory cytokine production in the lungs compared to other VLP immunization groups. In correlation with these findings, the lowest bodyweight losses and lung virus titers were observed from HANA VLP immunization, and all of the immunized mice survived irrespective of the challenge dose. Contrastingly, VLPs expressing either HA or NA alone failed to elicit complete protection. These results indicated that NA in VLPs played a critical role in inducing protection against a high dose of the challenge infection.

Citing Articles

Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.

Adeleke R, Sahler J, Choi A, Roth K, Upadhye V, Ezzatpour S Sci Adv. 2025; 11(5):eadq4545.

PMID: 39879304 PMC: 11777205. DOI: 10.1126/sciadv.adq4545.

Immunizing Mice with Influenza Virus-like Particles Expressing the Promastigote Surface Antigen Alleviates Inflammation in Footpad.

Eom G, Chu K, Yoon K, Mao J, Kim S, Quan F Vaccines (Basel). 2024; 12(7).

PMID: 39066431 PMC: 11281337. DOI: 10.3390/vaccines12070793.

Anti-neuraminidase immunity in the combat against influenza.

Zhang X, Ross T Expert Rev Vaccines. 2024; 23(1):474-484.

PMID: 38632930 PMC: 11157429. DOI: 10.1080/14760584.2024.2343689.

Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo.

Lee D, Jo H, Jang Y, Bae S, Agura T, Kang D Int J Mol Sci. 2023; 24(1).

PMID: 36614125 PMC: 9820929. DOI: 10.3390/ijms24010678.

Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus.

Kang H, Chu K, Yoon K, Eom G, Mao J, Quan F Biomedicines. 2022; 10(7).

PMID: 35884922 PMC: 9313027. DOI: 10.3390/biomedicines10071618.

References

Fielding J, Kelly H, Mercer G, Glass K . Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses. 2013; 8(2):142-50. PMC: 4186461. DOI: 10.1111/irv.12216. View

Deng R, Lu M, Korteweg C, Gao Z, McNutt M, Ye J . Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patients. J Pathol. 2008; 216(3):328-36. DOI: 10.1002/path.2417. View

La Gruta N, Turner S . T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol. 2014; 35(8):396-402. DOI: 10.1016/j.it.2014.06.004. View

Lai S, Qin Y, Cowling B, Ren X, Wardrop N, Gilbert M . Global epidemiology of avian influenza A H5N1 virus infection in humans, 1997-2015: a systematic review of individual case data. Lancet Infect Dis. 2016; 16(7):e108-e118. PMC: 4933299. DOI: 10.1016/S1473-3099(16)00153-5. View

Nakajima N, Van Tin N, Sato Y, Thach H, Katano H, Diep P . Pathological study of archival lung tissues from five fatal cases of avian H5N1 influenza in Vietnam. Mod Pathol. 2012; 26(3):357-69. DOI: 10.1038/modpathol.2012.193. View

Short K, Richard M, Verhagen J, van Riel D, Schrauwen E, van den Brand J . One health, multiple challenges: The inter-species transmission of influenza A virus. One Health. 2015; 1:1-13. PMC: 4542011. DOI: 10.1016/j.onehlt.2015.03.001. View

Noad R, Roy P . Virus-like particles as immunogens. Trends Microbiol. 2003; 11(9):438-44. DOI: 10.1016/s0966-842x(03)00208-7. View

Wong S, DeBeauchamp J, Zanin M, Sun Y, Tang L, Webby R . H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines. NPJ Vaccines. 2017; 2:16. PMC: 5627238. DOI: 10.1038/s41541-017-0017-5. View

Wu C, Yeh Y, Chan J, Yang Y, Yang J, Liu M . A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One. 2012; 7(8):e42363. PMC: 3413679. DOI: 10.1371/journal.pone.0042363. View

10.

Leyson C, Youk S, Smith D, Dimitrov K, Lee D, Larsen L . Pathogenicity and genomic changes of a 2016 European H5N8 highly pathogenic avian influenza virus (clade 2.3.4.4) in experimentally infected mallards and chickens. Virology. 2019; 537:172-185. PMC: 6901708. DOI: 10.1016/j.virol.2019.08.020. View

11.

Chu K, Kang H, Yoon K, Lee H, Moon E, Han B . Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. Vaccines (Basel). 2021; 9(8). PMC: 8402567. DOI: 10.3390/vaccines9080920. View

12.

Wohlleben G, Muller J, Tatsch U, Hambrecht C, Herz U, Renz H . Influenza A virus infection inhibits the efficient recruitment of Th2 cells into the airways and the development of airway eosinophilia. J Immunol. 2003; 170(9):4601-11. DOI: 10.4049/jimmunol.170.9.4601. View

13.

Tretyakova I, Pearce M, Florese R, Tumpey T, Pushko P . Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013; 442(1):67-73. DOI: 10.1016/j.virol.2013.03.027. View

14.

Paulo A, Correia-Neves M, Domingos T, Murta A, Pedrosa J . Influenza infectious dose may explain the high mortality of the second and third wave of 1918-1919 influenza pandemic. PLoS One. 2010; 5(7):e11655. PMC: 2909907. DOI: 10.1371/journal.pone.0011655. View

15.

Skarlupka A, Bebin-Blackwell A, Sumner S, Ross T . Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains. J Virol. 2021; 95(17):e0075921. PMC: 8354223. DOI: 10.1128/JVI.00759-21. View

16.

Cornelissen L, de Vries R, de Boer-Luijtze E, Rigter A, Rottier P, de Haan C . A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1. PLoS One. 2010; 5(5):e10645. PMC: 2871037. DOI: 10.1371/journal.pone.0010645. View

17.

Kang Y, Cho H, Kim J, Lee S, Park S, Kim D . Single dose of multi-clade virus-like particle vaccine protects chickens against clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses. Sci Rep. 2021; 11(1):13786. PMC: 8253753. DOI: 10.1038/s41598-021-93060-8. View

18.

Smith T, OKennedy M, Wandrag D, Adeyemi M, Abolnik C . Efficacy of a plant-produced virus-like particle vaccine in chickens challenged with Influenza A H6N2 virus. Plant Biotechnol J. 2019; 18(2):502-512. PMC: 6953208. DOI: 10.1111/pbi.13219. View

19.

Kim K, Lee Y, Park S, Jung Y, Lee Y, Ko E . Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus. Virology. 2019; 535:179-188. PMC: 6946909. DOI: 10.1016/j.virol.2019.07.008. View

20.

Monto A, Petrie J, Cross R, Johnson E, Liu M, Zhong W . Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis. 2015; 212(8):1191-9. DOI: 10.1093/infdis/jiv195. View